Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Taylor Wesley

Physician Assistant Moberly, MO Physician Assistant

NPI 1598209512 CMS profile 10499945

300 N Morley St Ste A-C, Moberly, MO 65270

Open in the dashboard

General payments

$6,931

412 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Taylor Wesley of Moberly, MO is reported in the CMS Open Payments database as having received $6,931 across 412 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,303 73
2024 General $2,502 137
2023 General $1,497 92
2022 General $1,026 61
2021 General $602 49

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Taylor Wesley
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Taylor Wesley were reported at $1,303. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Taylor Wesley Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $602 $132 $37–$438 $132
2022 $1,026 $155 $48–$522 $149
2023 $1,497 $167 $52–$557 $160
2024 $2,502 $178 $55–$600 $164
2025 $1,303 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,281 96 payments
  2. AstraZeneca Pharmaceuticals LP $883 34 payments
  3. Novo Nordisk Inc $759 55 payments
  4. Amgen Inc. $705 39 payments
  5. Abbott Laboratories $561 25 payments
  6. Lilly USA, LLC $393 26 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $274 14 payments
  8. Pfizer Inc. $247 18 payments
  9. Bayer HealthCare Pharmaceuticals Inc. $236 12 payments
  10. Otsuka America Pharmaceutical, Inc. $189 10 payments
  11. Other $1,403 83 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,895 409 payments
  2. Education $36 3 payments
Products named General payments · program years 2021–2025
  1. BREZTRI $627 18 payments
  2. VRAYLAR $586 55 payments
  3. Ozempic $535 41 payments
  4. RYBELSUS $512 39 payments
  5. FARXIGA $502 14 payments
  6. FreeStyle Libre 3 $469 19 payments
  7. Otezla $440 25 payments
  8. Repatha $422 24 payments
  9. AIRSUPRA $383 6 payments
  10. UBRELVY $343 16 payments
  11. Other $4,675 280 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 155 drugs

Part D claims

8,234

Median for Physician Assistant: 241

Drug cost

$949,300

Median for Physician Assistant: $4,110

Branded share of claims

26.1%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 182 $193,676
Farxiga Dapagliflozin Propanediol Brand 180 $134,420
Mounjaro Tirzepatide Brand 64 $86,464
Eliquis Apixaban Brand 84 $65,703
Repatha Sureclick Evolocumab Brand 91 $61,878
Trulicity Dulaglutide Brand 40 $41,416
Nurtec Odt Rimegepant Sulfate Brand 20 $26,473
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 39 $25,467
Rexulti Brexpiprazole Brand 17 $23,295
Myrbetriq Mirabegron Brand 42 $23,042

The 10 drugs with the highest cost, of 155 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 50 billing codes

Paid by Medicare

$91,640

Of which drugs: $3,739

Medicare patients

307

Average age 74

Services billed

1,648

187 women, 120 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 46%
Ischemic heart disease 33%
Diabetes 32%
Chronic kidney disease 21%
Atrial fibrillation 20%
Depression 20%
COPD 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 27 27 $2,179

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 31 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $262
$262 15 —
REXULTI
  • Lundbeck LLC $83
  • Otsuka America Pharmaceutical, Inc. $62
$145 17 —
Ozempic
  • Novo Nordisk Inc $121
$121 182 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $113
$113 — —
RYBELSUS
  • Novo Nordisk Inc $112
$112 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 31 with Patron

Records

412 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record